Novartis Counts On Adherence, Access And Affordability To Ensure Inclisiran’s US Success

Drug Maker Refiles PCSK9 Inhibitor Leqvio After December CRL

The company has said coverage under medical benefit could mean $0 copays for many patients, potentially overcoming a hurdle to uptake in the biologic cholesterol market.

Doctor holding out your piggy bank wanting payment/ Your Savings To Pay Bill, insert coins to it,Stethoscope financial checkup or saving for medical insurance costs money plan fee Lifestyle concept
Novartis is aiming for adherence, access and affordability to ensure Leqvio's success in the US • Source: Shutterstock

In spite of its delayed timeline for US market entry, Novartis AG is hoping its strategy around inclisiran in atherosclerotic cardiovascular disease (ASCVD) – focusing on adherence, access and affordability – can ensure sufficient uptake of the twice-yearly PCSK9 inhibitor if it wins Food and Drug Administration approval.

The company has been busy at work developing a buy-and-bill infrastructure, as well as a network of injection centers, and...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from Business

More from Scrip